Nanoscope
Nanoscope co-founder and CEO Sulagna Bhattacharya
Nanoscope, the Bedford-based biotech company, said it was awarded a $1.5 million grant from the National Eye Institute of the National Institutes of Health that will advance development of the company's therapy for age-related macular degeneration.
“Winning the NIH grant via a highly competitive review process is a testament to the innovativeness and clinical significance" of the company's therapy, Sulagna Bhattacharya, CEO of Nanoscope, said. “Our goal is to apply our therapy to relieve the suffering of millions of people worldwide with AMD.”
Nanoscope’s lead gene therapy, MCO-010, is in a late-stage Phase 2b trial for retinitis pigmentosa in the United States.
Nanoscope Therapeutics is developing optogenetic therapies for giving sight to the millions of blind individuals suffering from retinal degenerative diseases, for which no cure exists.